Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | CDC7 | O00311 | 4/20 | 0.54 |
| ▸ | DBF4 | Q9UBU7 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8341574 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2CDC7DBF4ALDH1A1KDM4E | |
| SCHEMBL16703796 | 0.88 | SMN1; SMN2 (0.49) | SMN1; SMN2CDC7DBF4ALDH1A1KDM4E | |
| SCHEMBL8338941 | 0.88 | ALDH1A1 (0.54) | SMN1; SMN2CDC7DBF4ALDH1A1KDM4E | |
| SCHEMBL24303680 | 0.86 | RAB9A (0.48) | SMN1; SMN2CDC7DBF4ALDH1A1KDM4E | |
| SCHEMBL873941 | 0.86 | RAB9A (0.48) | SMN1; SMN2CDC7DBF4ALDH1A1KDM4E | |
| SCHEMBL290490 | 0.86 | CYP1A2 (0.53) | SMN1; SMN2CDC7DBF4ALDH1A1KDM4E | |
| SCHEMBL8338965 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2CDC7DBF4ALDH1A1KDM4E | |
| SCHEMBL3664702 | 0.82 | P2RX7 (0.46) | SMN1; SMN2CDC7DBF4ALDH1A1KDM4E | |
| SCHEMBL5641718 | 0.81 | CDC7 (0.68) | CDC7DBF4ALDH1A1KDM4EMAPT | |
| SCHEMBL14418958 | 0.81 | CDC7 (0.51) | SMN1; SMN2CDC7DBF4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015069011-A1 | NOVEL COMPOUND, METHOD FOR PREPARATION THEREOF, AND ANTIFUNGAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-14 | — | — | WO | disclosed |
| CN-102659774-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE | 2012-09-12 | — | — | CN | disclosed |
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| CN-101282972-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | CN | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-7273866-B2 | 2-aryl thiazole derivatives as KCNQ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
| US-20040147401-A1 | 2-aryl thiazole derivatives as KCNQ modulators | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004060281-A2 | 2-ARYL THIAZOLE DERIVATIVES AS KCNQ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | SMN1; SMN2 3624/4885CDC7 3776/4885DBF4 1455/4885 |
| US-20040147401-A1 | 2-aryl thiazole derivatives as KCNQ modulators | KCNJ2, KCNT1, KCNQ1 | SMN1; SMN2 2123/4885CDC7 3614/4885DBF4 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.